
Patel Chem Specialities Limited Reports 25.07% YoY Revenue Growth and 14.13% EBITDA Growth in H1 FY27

Ahmedabad, November 6, 2026 – Patel Chem Specialities Limited, a manufacturer of pharmaceutical excipients and speciality chemicals, **announced its unaudited financial results for the half year ended September 30, 2026 (H1 FY27).**

H1 FY27 Key Financial Highlights



Financial Highlights (In ₹ Lakhs)	H1 FY27	H1 FY26	YoY Change
Revenue from Operations	**7,649.10**	6,115.81	▲ 25.07%
EBITDA	**1,013.52**	888.07	▲ 14.13%
PAT	**626.90**	612.92	▲ 2.28 %

Key Highlights

1. **Revenue Growth**: Revenue from operations increased by 25.07% YoY to ₹76.49 crore in H1 FY27, compared with ₹61.16 crore in H1 FY26, reflecting higher reported business revenue during the period.

2. **Manufacturing Capacity Expansion:** The Company has successfully completed its second expansion at the Talod facility, increasing annual production capacity from 720 MT to 4,500 MT. The expansion involved capital expenditure of approximately ₹20 crore, funded through bank loans and internal accruals. Trial batches have commenced, with commercial production expected to begin shortly, supporting growing market demand and faster delivery schedules.
3. **Earnings Performance**: EBITDA increased by 14.13% YoY to ₹10.14 crore, compared with ₹8.88 crore in H1 FY26. PAT increased by 2.28% YoY to ₹6.27 crore, while EBITDA and PAT margins moderated by 127 bps and 183 bps, respectively.
4. **Strengthening Shareholders' Funds**: Shareholders' funds increased to ₹105.77 crore as of September 30, 2026, compared with ₹99.50 crore as of March 31, 2026, reflecting an increase of approximately 6.30%.
5. **Investment in Capital Work-in-Progress**: Capital work-in-progress increased to ₹21.86 crore as of September 30, 2026, from ₹14.51 crore as of March 31, 2026, reflecting an increase of approximately 50.66%. The financial results do not specify the commissioning timeline or additional manufacturing capacity.
6. **Cash and bank balances** stood at ₹31.04 crore as of September 30, 2026. Total long-term and short-term borrowings stood at ₹23.74 crore, compared with ₹15.23 crore at the end of FY26.

Management Commentary

Commenting on the development, **Mr. Bhupesh Patel, Managing Director of Patel Chem Specialities Limited** said: *"We are pleased to report revenue growth of 25.07% during H1 FY27, reflecting the continued progress of our business in pharmaceutical excipients and speciality chemicals.*

Our EBITDA increased by 14.13%, while profit after tax grew by 2.28% year-on-year. Although margins moderated during the period, we remain focused on improving operational efficiency and managing costs effectively.

During the first half, our capital work-in-progress increased to ₹21.86 crore, reflecting ongoing capital deployment. Our shareholders' funds also strengthened to ₹105.77 crore as of September 30, 2026.

Going forward, our focus will remain on strengthening our operational capabilities, maintaining financial discipline, improving working capital efficiency and supporting sustainable long-term business growth."

About Patel Chem Specialities Limited

Patel Chem Specialities Limited operates in the specialty chemicals industry, with a focus on cellulose-based excipients and speciality chemicals used across pharmaceutical, food & beverage, cosmetics and industrial applications. With a diversified **B2B customer base**, the Company caters **to both domestic and international** markets, with its products finding applications across regulated and quality-sensitive industries. The Company's operations are supported by a strong focus on quality, regulatory compliance and consistent product standards, with certifications including **US-DMF, GMP and ISO 9001:2015**.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Investor Relations Partner

ORIM CONNECT
+(91) 83693 82388
letsconnect@orim.in
www.orim.in/orim-connect/